NCT05222984 2026-04-20
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
City of Hope Medical Center
Phase 1 Active not recruiting
Clinical Trials
10 trialsNCT05455294 2026-01-28
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05564650 2025-12-08
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Active not recruiting
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT05358639 2024-11-18
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Sunnybrook Health Sciences Centre
Phase 1 Active not recruiting
NCT06007911 2024-08-13
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 1 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05054465 2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2 Not yet recruiting
NCT02591095 2019-03-19
MONAVI-1
Centre Francois Baclesse
Phase 2 Completed
NCT01828476 2017-05-04
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated